Inhibitory effect of low-dose pentazocine on the development of antinociceptive tolerance to morphine

Journal of Anesthesia

Volumn 23, Issue 1, 2009, Pages 99-107

  Chiba, Shunsuke ^a   Hayashida, Masakazu ^a,b   Yoshikawa, Masanobu ^c   Shu, Haihua ^a   Nishiyama, Tomoki ^a   Yamada, Yoshitsugu ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^c TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Agonist antagonist; Morphine; Pentazocine; Tail pressure test; Tolerance

Indexed keywords

CLOCINNAMOX; MORPHINE; NORBINALTORPHIMINE; PENTAZOCINE; SODIUM CHLORIDE;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG POTENTIATION; INSTITUTE FOR CANCER RESEARCH MOUSE; LOW DRUG DOSE; MALE; MORPHINE TOLERANCE; MOUSE; NONHUMAN; PAIN; PAIN THRESHOLD; REPEATED DRUG DOSE; SINGLE DRUG DOSE;

ANALGESICS, OPIOID; ANIMALS; CINNAMATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; MALE; MICE; MICE, INBRED ICR; MORPHINE; MORPHINE DERIVATIVES; NALTREXONE; NARCOTIC ANTAGONISTS; PAIN MEASUREMENT; PENTAZOCINE; PRESSURE; RECEPTORS, OPIOID, KAPPA;

EID: 61349203935     PISSN: 09138668     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00540-008-0697-0     Document Type: Article

References (35)

1. Foley KM. Controlling cancer pain. Hosp Pract. 2000;35:101-108, 111-2.
2. Elliott K, Kest B, Man A, Kao B, Inturrisi CE. N-Methyl-Daspartate (NMDA) receptors, mu and kappa opioid tolerance, and perspectives on new analgesic drug development. Neuropsychopharmacology. 1995;13:347-356.
3. Pan ZZ. mu-Opposing actions of kappa-opioid receptor. Trends Pharmacol Sci. 1998;19:94-98.
4. Visser E, Schug SA. The role of ketamine in pain management. Biomed Pharmacother. 2006;60:341-348.
5. Dudgeon DJ, Bruera E, Gagnon B, Watanabe SM, Allan SJ, Warr DG, MacDonald SM, Savage C, Tu D, Pater JL. A phase III randomized, double-blind, placebo-controlled study evaluating dextromethorphan plus slow-release morphine for chronic cancer pain relief in terminally ill patients. J Pain Symptom Manage. 2007;33:365-371.
6. Shu H, Hayashida M, Huang W, An K, Chiba S, Hanaoka K, Arita H. The comparison of effects of processed Aconiti tuber, U50488H and MK-801 on the antinociceptive tolerance to morphine. J Ethnopharmacol. 2008;117:158-165.
7. Gutstein HB, Akil H. Opioid analgesics. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman and Gilman's: The pharmacological basis of therapeutics. New York: McGrawHill/Hardman; 2006. p. 547-590.
8. Pfeiffer A, Brantl V, Herz A, Emrich HM. Psychotomimesis mediated by κ-opiate receptors. Science. 1986;233:774-776.
9. Walsh SL, Strain EC, Abreu ME, Bigelow GE. Enadoline, a selective kappa opioid agonist: Comparison with butorphanol and hydromorphone in humans. Psychopharmacology. 2001;157:151-162.
10. Dortch-Carnes J, Potter DE. Bremazocine: A kappa-opioid agonist with potent analgesic and other pharmacologic properties. CNS Drug Rev. 2005;11:195-212.
11. Omiya Y, Goto K, Suzuki Y, Ishige A, Komatsu Y. Analgesia-producing mechanism of processed Aconiti tuber: Role of dynorphin, an endogenous kappa-opioid ligand, in rodent spinal cord. Jpn J Pharmacol. 1999;79:295-301.
12. Shu H, Arita H, Hayashida M, Sekiyama H, Hanaoka K. Effects of processed Aconiti tuber and its ingredient alkaloids on the development of antinociceptive tolerance to morphine. J Ethnopharmacol. 2006;103:398-405.
13. Shu H, Arita H, Hayashida M, Chiba S, Sekiyama H, Hanaoka K. Inhibition of morphine tolerance by processed Aconiti tuber is mediated by kappa-opioid receptors. J Ethnopharmacol. 2006;106:263-271.
14. Shu H, Hayashida M, Chiba S, Sekiyama H, Kitamura T, Yamada Y, Hanaoka K, Arita H. Inhibitory effect of processed Aconiti tuber on the development of antinociceptive tolerance to morphine: Evaluation with a thermal assay. J Ethnopharmacol. 2007;113:560-563.
15. Hoskin PJ, Hanks GW. Opioid agonist-antagonist drugs in acute and chronic pain states. Drugs. 1991;41:326-344.
16. Takemori AE, Ho BY, Naeseth JS, Portoghese PS. Norbinaltorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays. J Pharmacol Exp Ther. 1988;246:255-258.
17. Endoh T, Matsuura H, Tanaka C, Nagase H. Nor-binaltorphimine: A potent and selective kappa-opioid receptor antagonist with long-lasting activity in vivo. Arch Int Pharmacodyn Ther. 1992;316:30-42.
18. Zernig G, Burke T, Lewis JW, Woods JH. Mechanism of clocinnamox blockade of opioid receptors: Evidence from in vitro and ex vivo binding and behavioral assays. J Pharmacol Exp Ther. 1996;279:23-31.
19. Paronis CA, Woods JH. Clocinnamox dose-dependently antagonizes morphine analgesia and [3H] DAMGO binding in rats. Eur J Pharmacol. 1997;337:27-34.
20. Tulunay FC, Jen MF, Chang JK, Loh HH, Lee NM. Possible regulatory role of dynorphin on morphine- and beta-endorphin-induced analgesia. J Pharmacol Exp Ther. 1981;219:296-298.
21. Schmauss C, Herz A. Intrathecally administered dynorphine-(1-17) modulates morphine-induced antinociception differently in morphine-naïve and morphine-tolerant rats. Eur J Pharmacol. 1987;135:429-431.
22. Ramarao P, Jablonski HI Jr, Rehder KR, Bhargava HN. Effect of kappa-opioid receptor agonists on morphine analgesia in morphine-naïve and morphine-tolerant rats. Eur J Pharmacol. 1988;156:239-246.
23. Tao PL, Hwang CL, Chen CY. U-50,488 blocks the development of morphine tolerance and dependence at a very low dose in guinea pigs. Eur J Pharmacol. 1994;256:281-286.
24. Varga EV, Yamamura HI, Rubenzik MK, Stropova D, Navratilova E, Roeske WR. Molecular mechanisms of excitatory signaling upon chronic opioid agonist treatment. Life Sci. 2003;74:299-311.
25. Ossipov MH, Lai J, King T, Vanderah TW, Porreca F. Underlying mechanisms of pronociceptive consequences of prolonged morphine exposure. Biopolymers. 2005;80:319-324.
26. Pan ZZ, Tershner SA, Fields HL. Cellular mechanism for anti-analgesic action of agonists of the kappa-opioid receptor. Nature. 1997;389:382-385.
27. Bie B, Pan ZZ. Presynaptic mechanism for anti-analgesic and anti-hyperalgesic actions of kappa-opioid receptors. J Neurosci. 2003;23:7262-7268.
28. Blane GF, Dugdall D. Interactions of narcotic antagonists and antagonist-analgesics. J Pharm Pharmacol. 1968;20:547-552.
29. Suzuki T, Narita M, Misawa M, Nagase H. Pentazocine-induced biphasic analgesia in mice. Life Sci. 1991;48:1827-1835.
30. Shimada A, Iizuka H, Yanagita T. Agonist-antagonistic interactions of pentazocine with morphine studied in mice. Pharmacol Biochem Behav. 1984;20:531-535.
31. Tokuyama S, Nagase R, Mashida E, Hamabe W. Involvement of kappa opioid receptors in formalin-induced inhibition of analgesic tolerance to morphine in mice. J Pharm Pharmacol. 2007;59:1109-1115.
32. Tsuji M, Yamazaki M, Takeda H, Matsumiya T, Nagase H, Tseng LF, Narita M, Suzuki T. The novel kappa-opioid receptor agonist TRK-820 has no affect on the development of antinociceptive tolerance to morphine in mice. Eur J Pharmacol. 2000;394:91-95.
33. Wakabayashi H, Hiraga T, Yoneda T. Mechanism of cancer-induced bone pain. Clin Calcium. 2006;16:605-611.
34. Backonja MM, Miletic G, Miletic V. The effect of continuous morphine analgesia on chronic thermal hyperalgesia due to sciatic constriction injury in rats. Neurosci Lett. 1995;196:61-64.
35. Raghavendra V, Rutkowski MD, DeLeo JA. The role of spinal neuroimmune activation in morphine tolerance/hyperalgesia in neuropathic and sham-operated rats. J Neurosci. 2002;2:9980-9989.